natgillin/translations-raw huggingface dataset:
The risk of withdrawal symptoms seen with SSRI's and SNRI's may be dependent on several factors including the duration and dose of therapy and the rate of dose reduction. 
Tveganje za pojav odtegnitvenih simptomov opaženih pri SSRI in SNRI je odvisno od številnih dejavnikov, med drugim od trajanja zdravljenja in predpisanega odmerka ter stopnje zmanjševanja odmerka zdravila.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. 
Preobčutljivost za učinkovino ali katerokoli pomožno snov, navedeno v poglavju 6.1.
CNS medicinal products: The risk of using duloxetine in combination with other CNS-active medicinal products has not been systematically evaluated, except in the cases described in this section. 
Zdravila CŽS: tveganja uporabe duloksetina v kombinaciji z drugimi zdravili, ki delujejo na CŽS, niso sistematično vrednotili, razen v primerih, opisanih v tem poglavju.
• throat inflammation that causes a hoarse voice 
• vnetje grla, ki povzroči hripav glas
In patients with insufficient response the dose should be increased to 60 mg, which is the usual maintenance dose in most patients. 
Pri bolnikih z nezadostnim odgovorom moramo odmerek zvišati na 60 mg, kar je običajen vzdrževalni odmerek pri večini bolnikov.
In patients who develop these symptoms, increasing the dose may be detrimental. 
Za bolnike z omenjenimi simptomi je večanje odmerka lahko škodljivo.
• fast and/or irregular heart beat 
• hitro ali nepravilno bitje srca
However, there is no clinical evidence suggesting that patients not responding to the initial recommended dose may benefit from dose up-titrations. 
Vendar pa ni kliničnih dokazov, ki bi kazali, da lahko bolnikom, ki se na priporočeni začetni odmerek ne odzovejo, povišanja odmerka koristijo.
Duloxetine is approximately 96% bound to human plasma proteins. 
Duloksetin se veže na človeške plazemske beljakovine v približno 96 %.
Women should be advised to notify their physician if they become pregnant, or intend to become pregnant, during therapy. 
Ženskam je treba svetovati, naj obvestijo zdravnika, če med zdravljenjem zanosijo ali načrtujejo nosečnost.
It may make you feel sleepy or dizzy. 
Lahko povzroči občutek zaspanosti ali omotice.
Do not start or stop taking any medicines, including those bought without a prescription and herbal remedies, before checking with your doctor. 
Ne začnite jemati niti ne prenehajte jemati katerihkoli zdravil, vključno s tistimi, ki ste jih kupili brez recepta, in pripravkov rastlinskega izvora, ne da bi se pred tem posvetovali z zdravnikom.
The same precautions observed when treating patients with major depressive disorder should therefore be observed when treating patients with other psychiatric disorders. 
Iste previdnostne ukrepe, ki jih izvajamo pri zdravljenju bolnikov z veliko depresivno motnjo, moramo torej izvajati tudi pri zdravljenju bolnikov z drugimi psihiatričnimi motnjami.
Specific in vivo drug interaction studies have not been performed. 
Specifične študije in vivo medsebojnega delovanja zdravil niso bile opravljene.
These symptoms are usually not serious and disappear within a few days, but if you have symptoms that are troublesome you should ask your doctor for advice. 
Ti simptomi običajno niso resni in v nekaj dneh izzvenijo, vendar se posvetujte z zdravnikom, če imate simptome, ki vam povzročajo težave.
If your baby has any of these symptoms when it is born, or you are concerned about your baby's health, contact your doctor or midwife who will be able to advise you. 
Če ima vaš dojenček ob rojstvu kateregakoli od teh simptomov ali vas skrbi dojenčkovo zdravje, se obrnite na zdravnika ali babico, ki vam bosta znala svetovati.
In animal studies, duloxetine had no effect on male fertility, and effects in females were only evident at doses that caused maternal toxicity. 
V študijah na živalih duloksetin ni vplival na plodnost pri moških, pri ženskah pa so bili učinki opaženi le pri odmerkih, ki so povzročili toksičnost za mater.
If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. 
V primeru, da se ob zmanjšanju odmerka ali prekinitvi zdravljenja pojavijo nevzdržni simptomi, je treba razmisliti o ponovni uvedbi prej predpisanega odmerka.
The absolute oral bioavailability of duloxetine ranged from 32% to 80% (mean of 50%). 
Absolutna peroralna biološka uporabnost duloksetina dosega vrednosti od 32 do 80 % (povprečje 50 %).
The majority of cases have occurred either at birth or within a few days of birth. 
Do večine primerov je prišlo ob rojstvu ali v nekaj dneh po tem.
The pharmacokinetics of duloxetine demonstrate large intersubject variability (generally 50-60%), partly due to gender, age, smoking status and CYP2D6 metaboliser status. 
Farmakokinetika duloksetina kaže veliko variabilnost med osebki (na splošno 50-60 %), deloma zaradi spola, starosti, kajenja in stanja presnavljanja s CYP2D6.
• problems getting an erection, changes in ejaculation 
• težave z erekcijo, spremembe v ejakulaciji
If your doctor has prescribed Duloxetine Lilly for a patient under 18 and you want to discuss this, please go back to your doctor. 
Če je zdravnik predpisal zdravilo Duloksetin Lilly bolniku, mlajšemu od 18 let, in se želite o tem pogovoriti, se, prosimo, obrnite na zdravnika.
The dose may be adjusted up to 120 mg a day based on your response to Duloxetine Lilly. 
Odmerek bo morda prilagojen do 120 mg na dan, glede na vaš odziv na zdravilo Duloksetin Lilly.
Some patients who stop taking Duloxetine Lilly suddenly have had symptoms such as: 
Nekateri bolniki, ki so nenadoma prenehali jemati zdravilo Duloksetin Lilly, so imeli simptome, kot so:
They usually occur within the first few days of discontinuing treatment, but there have been very rare reports of such symptoms in patients who have inadvertently missed a dose. 
Večinoma se pojavijo v prvih dneh po prekinitvi zdravljenja, vendar so o njih redko poročali tudi pri bolnikih, ki so nenamerno izpustili odmerek zdravila.
Other psychiatric conditions for which Duloxetine Lilly is prescribed can also be associated with an increased risk of suicide-related events. 
Druga psihiatrična stanja, za katera predpisujemo zdravilo Duloksetin Lilly so tudi lahko povezana z večjim tveganjem za pojav dogodkov povezanih s samomorom.
The primary outcome measure was the weekly mean of 24-hour average pain, which was collected in a daily diary by patients on an 11-point Likert scale. 
Primarna mera izida je bilo tedensko povprečje 24-urne povprečne bolečine, kar smo zbrali iz dnevnih dnevnikov bolnikov na podlagi 11točkovne Likertove lestvice.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription. 
Obvestite zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali, ali pa boste morda začeli jemati katerokoli zdravilo, tudi če ste ga dobili brez recepta.
After consolidation of the antidepressive response, it is recommended to continue treatment for several months, in order to avoid relapse. 
Po utrditvi odziva na antidepresivno zdravilo je priporočljivo nadaljevati zdravljenje še nekaj mesecev, da se izognemo relapsu.
2 Cases of orthostatic hypotension and syncope have been reported especially at the initiation of treatment. 
2O primerih ortostatske hipotenzije in sinkope so poročali zlasti ob začetku zdravljenja.
Taking a MAOI together with many prescription medicines, including Duloxetine Lilly, can cause serious or even life-threatening side effects. 
Jemanje MAOI skupaj z mnogimi zdravili na recept, vključno z zdravilom Duloksetin Lilly, lahko povzroči resne ali celo smrtno nevarne neželene učinke.
The no-adverse effect level was determined to be 20 mg/kg/day. 
Meja, pri kateri ni bilo neželenih učinkov, je bila 20 mg/kg/dan.
Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrose-isomaltase insufficiency should not take this medicine. 
Bolniki z redko dedno intoleranco za fruktozo, malabsorpcijo glukoze/galaktoze ali pomanjkanjem saharoze-izomaltaze ne smejo jemati tega zdravila
Major Depressive Disorder and Generalised Anxiety Disorder: Depression is associated with an increased risk of suicidal thoughts, self harm and suicide (suicide-related events). 
Velike depresivne motnje in generalizirana anksiozna motnja: depresija je povezana z večjim tveganjem za pojav samomorilnih misli, samopoškodovanje in samomorilnosti (s samomorom povezani dogodki).
• suicidal behaviour, mania (over activity, racing thoughts and decreased need for sleep), hallucinations, aggression and anger 
• samomorilno vedenje, manija (prevelika aktivnost, bežeče misli in zmanjšana potreba po spanju), halucinacije, agresivnost in jeza
Also, you should know that patients under 18 have an increased risk of side-effects such as suicide attempt, suicidal thoughts and hostility (predominantly aggression, oppositional behaviour and anger) when they take this class of medicines. 
Prav tako se moramo zavedati, da imajo bolniki, mlajši od 18 let, večje tveganje za neželene učinke, denimo poskus samomora, samomorilne misli in sovražnost (zlasti nasilnost, nasprotovalno vedenje in jezo), kadar jemljejo zdravila iz te skupine.
Duloxetine Lilly with food, drink and alcohol 
Zdravilo Duloksetin Lilly skupaj s hrano, pijačo in z alkoholom
Each capsule may contain up to 111 mg sucrose. 
Ena kapsula lahko vsebuje do 111 mg saharoze.
• Stevens-Johnson syndrome (serious illness with blistering of the skin, mouth, eyes and genitals), serious allergic reaction which causes swelling of the face or throat (angioedema) 
• Stevens-Johnsonov sindrom (resna bolezen z mehurji na koži, ustih, očeh in genitalijah), resne alergične reakcije, ki povzročijo otekanje obraza ali grla (angioedem)
Duloxetine was not genotoxic in a standard battery of tests and was not carcinogenic in rats. 
Duloksetin v standardnih testih ni bil genotoksičen in pri podganah ni bil kancerogen.
Discontinuation of duloxetine (particularly when abrupt) commonly leads to withdrawal symptoms. 
Prekinitev zdravljenja z duloksetinom (še zlasti, če je nenadna) pogosto povzroči odtegnitvene simptome.
4 Cases of aggression and anger have been reported particularly early in treatment or after treatment discontinuation. 
4O primerih agresije in jeze so poročali zlasti ob začetku zdravljenja in po prekinitvi zdravljenja.
Examples of MAOIs include moclobemide (an antidepressant) and linezolid (an antibiotic). 
Primeri MAOI vključujejo moklobemid (antidepresiv) in linezolid (antibiotik).
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. 
Nosečnost in dojenje Če ste noseči ali dojite, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte se z zdravnikom ali s farmacevtom, preden vzamete to zdravilo.
Epidemiological data have suggested that the use of SSRIs in pregnancy, particularly in late pregnancy, may increase the risk of persistent pulmonary hypertension in the newborn (PPHN). 
Epidemiološki podatki kažejo, da uporaba SSRI v nosečnosti, še posebej v pozni nosečnosti, lahko povečala tveganje za primarno pljučno hipertenzijo pri novorojenčkih (PPHN - persistent pulmonary hypertension in the newborn).
A conclusion on the overall benefit/risk in this age group has not been established (see also sections 4.2 and 4.8). 
Zaključek glede splošnih koristi/tveganj pri tej starostni skupini ni bil podan (glejte tudi poglavji 4.2
Pharmacokinetic differences have been identified between males and females (apparent plasma clearance is approximately 50% lower in females). 
Med moškimi in ženskami so ugotovili farmakokinetične razlike (očitni plazemski očistek je pri ženskah približno 50 % nižji).
Duloxetine has a large volume of distribution and forced diuresis, haemoperfusion, and exchange perfusion are unlikely to be beneficial. 
Duloksetin ima velik volumen porazdelitve, zato ni verjetno, da bi bile forsirana diureza, hemoperfuzija in izmenjevalna perfuzija koristne.
• increased blood pressure, flushing 
• povišan krvni tlak, zardevanje
In patients with co-morbid major depressive disorder, the starting and maintenance dose is 60 mg once daily (please see also dosing recommendation above). 
Pri bolnikih s sočasnimi veliki depresivnimi motnjami je začetni in vzdrževalni odmerek 60 mg enkrat na dan (prosimo glejte tudi priporočila za odmerjanje zgoraj).
Oral contraceptives and other steroidal agents: Results of in vitro studies demonstrate that duloxetine does not induce the catalytic activity of CYP3A. 
Peroralni kontraceptivi in druge steroidne učinkovine: rezultati študij in vitro kažejo, da duloksetin ne inducira katalitske aktivnosti CYP3A.
1 Cases of convulsion and cases of tinnitus have also been reported after treatment discontinuation. 
1O primerih konvulzij in o primerih tinitusa so poročali tudi po prekinitvi zdravljenja.
The study included a 10 week placebo-controlled acute phase, followed by an 18 week extension treatment period. 
Študija je vključevala 10-tedensko akutno fazo, kontrolirano s placebom, ki ji je sledilo 18-tedensko obdobje podaljšanega zdravljenja.
Weight increased to match other children and adolescents of their age and sex after 6 months of treatment. 
Telesna masa se je po šestih mesecih zdravljenja izenačila z otroki in mladostniki njihove starosti in spola.
• Tell your doctor if you become pregnant, or you are trying to become pregnant, while you are taking Duloxetine Lilly. 
• Obvestite zdravnika, če zanosite ali poskušate zanositi, medtem ko jemljete zdravilo Duloksetin
Blood pressure and heart rate 
Krvni tlak in srčna frekvenca
Do not stop taking Duloxetine Lilly, or change your dose, without talking to your doctor. 
Ne prenehajte jemati zdravila Duloksetin Lilly in ne spreminjajte odmerka, ne da bi se posvetovali z zdravnikom.
During the 10-week acute treatment period, suicidal behaviours were reported (duloxetine 0/333 [0%], fluoxetine 2/225 [0.9%], placebo 1/220 [0.5%]). 
Med 10-tedenskim obdobjem akutnega zdravljenja so poročali o samomorilnem vedenju (duloksetin 0/333 [0%], fluoksetin 2/225 [0,9%], placebo 1/220 [0,5%]).
In people with diabetic neuropathic pain it can take some weeks before you feel better. 
Pri bolnikih z bolečino diabetične nevropatije lahko traja več tednov, preden se vaše počutje izboljša.
A flexible dose regimen was used in this study, to allow for slow dose escalation from 30 mg once daily to higher doses (maximum 120 mg once daily). 
V tej študiji so uporabili fleksibilen režim odmerjanja, ki je omogočal počasno dviganje odmerka s 30 mg enkrat na dan do višjih odmerkov (največ 120 mg enkrat na dan).
In patients with insufficient response to 60 mg, escalation up to 90 mg or 120 mg may therefore be considered. 
Pri bolnikih z nezadostnim odgovorom na 60 mg odmerek lahko razmislimo o zvišanju do 90 mg ali 120 mg.
Studies in juvenile rats reveal transient effects on neurobehaviour, as well as significantly decreased body weight and food consumption; hepatic enzyme induction; and hepatocellular vacuolation at 45 mg/kg/day. 
Študije na mladih podganah kažejo na prehodne učinke na nevrološki vedenjski vzorec ter na znatno zmanjšanje telesne mase in uživanje hrane, indukcijo jeternih encimov in hepatocelularno vakuolacijo pri 45 mg/kg/dan.
No specific antidote is known for duloxetine but if serotonin syndrome ensues, specific treatment (such as with cyproheptadine and/or temperature control) may be considered. 
Specifičnega antidota za duloksetin ne poznamo, vendar v primeru pojava serotoninskega sindroma pretehtamo možnost uvedbe specifičnega zdravljenja (s ciproheptadinom in/ali nadzorom temperature).
If your doctor thinks that you no longer need Duloxetine Lilly he or she will ask you to reduce your dose over at least 2 weeks before stopping treatment altogether. 
Če bo zdravnik menil, da zdravila Duloksetin Lilly ne potrebujete več, vam bo naročil-a, da pred prenehanjem zdravljenja 2 tedna postopoma znižujte svoj odmerek.
Generally, for SSRIs and SNRIs, these events are mild to moderate and self-limiting, however, in some patients they may be severe and/or prolonged. 
Navadno so pri SSRI in SNRI ti dogodki blagi do zmerni in samoomejujoči, vendar so pri nekaterih bolnikih lahko resni in/ali trajajo dlje.
Major Depressive Disorder: Duloxetine Lilly was studied in a clinical programme involving 3,158 patients (1,285 patient-years of exposure) meeting DSM-IV criteria for major depression. 
Velike depresivne motnje: zdravilo Duloksetin Lilly so preučevali v kliničnem programu, v katerem je sodelovalo 3.158 bolnikov (1.285 bolniških let izpostavljenosti), ki so izpolnjevali merila DSM-IV za veliko depresivno motnjo.
Hyponatraemia may be due to a syndrome of inappropriate antidiuretic hormone secretion (SIADH). 
Hiponatriemija je lahko posledica sindroma neustreznega izločanja antidiuretičnega hormona (syndrome of inappropriate anti-diuretic hormone secretion, SIADH).
You should use Duloxetine Lilly only after discussing the potential benefits and any potential risks to your unborn child with your doctor. 
Zdravilo Duloksetin Lilly lahko uporabljate le po tem, ko ste se o možnih koristih in morebitnih možnih tveganjih za vašega nerojenega otroka pogovorili z zdravnikom.
The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal. 
Zahteve glede predložitve rednega posodobljenega poročila o varnosti zdravila za to zdravilo so določene v seznamu referenčnih datumov Unije (seznamu EURD), opredeljenem v členu 107c(7)
Polyvinylchloride (PVC), polyethylene (PE), and polychlorotrifluoroethylene (PCTFE) blister sealed with an aluminium foil. 
Pretisni omot iz polivinilklorida (PVC), polietilena (PE) in poliklorotrifluoroetilena (PCTFE), zaprt z aluminijasto folijo.
Moderate liver disease (Child Pugh Class B) affected the pharmacokinetics of duloxetine. 
Zmerno okvarjeno delovanje jeter (razred Child Pugh B) je vplivalo na farmakokinetiko duloksetina.
However, as with any medicine, caution should be exercised when treating the elderly, especially with Duloxetine Lilly 120 mg per day for major depressive disorder or generalised anxiety disorder, for which data are limited (see sections 4.4 and 5.2). 
Vendar pa je, kot pri vseh zdravilih, pri zdravljenju starejših potrebna previdnost, posebno z zdravilom Duloksetin Lilly 120 mg na dan za zdravljenje velike depresivne motnje ali generalizirane anksiozne motnje, za kar je na voljo malo podatkov (glejte poglavji 4.4 in 5.2).
Duloxetine Lilly should be used in pregnancy only if the potential benefit justifies the potential risk to the foetus. 
Zdravilo Duloksetin Lilly naj se v nosečnosti uporablja le, če možna korist upravičuje možno tveganje za plod.
Cases of overdoses, alone or in combination with other medicinal products, with duloxetine doses of 5400 mg were reported. 
Poročali so o primerih prevelikega odmerjanja duloksetina samega ali v kombinaciji z drugimi zdravili, s 5400 mg odmerki duloksetina.
Patients (and caregivers of patients) should be alerted about the need to monitor for any clinical worsening, suicidal behaviour or thoughts and unusual changes in behaviour and to seek medical advice immediately if these symptoms present. 
Bolnike (in njihove skrbnike) je treba opozoriti, da morajo biti pozorni na kakršnokoli klinično poslabšanje, pojav samomorilnega vedenja, misli na samomor in pojav neobičajnih vedenjskih sprememb, ter da se morajo v primeru, da takšni simptomi ne minejo, nemudoma posvetovati z zdravnikom.
Also, the long-term safety effects concerning growth, maturation, and cognitive and behavioural development of Duloxetine Lilly in this age group have not yet been demonstrated. 
Dolgoročni učinki zdravila Duloksetin Lilly na varnost glede rasti, dozorevanja in kognitivnega ter vedenjskega razvoja v tej starostni skupini tudi še niso bili ugotovljeni.
Myoclonus Akathisia7 
Mioklonus Akatizija7
For depression and diabetic neuropathic pain: 
Za depresijo in bolečino diabetične nevropatije:
Inducers of CYP1A2: Population pharmacokinetic analyses have shown that smokers have almost 50% lower plasma concentrations of duloxetine compared with non-smokers. 
Induktorji CYP1A2: analize populacijske farmakokinetike so pokazale, da imajo kadilci v primerjavi z nekadilci skoraj za 50 % nižje plazemske koncentracije duloksetina.
Duloxetine is extensively metabolised and the metabolites are excreted principally in urine. 
Duloksetin se obsežno presnavlja, presnovki se izločajo predvsem v urinu.
Duloxetine Lilly starts to work in most people with depression or anxiety within two weeks of starting treatment, but it may take 2-4 weeks before you feel better. 
Pri večini bolnikov z depresijo ali anksioznostjo začne zdravilo Duloksetin Lilly delovati v dveh tednih po začetku zdravljenja, lahko pa traja 2 do 4 tedne, preden se boste počutili boljše.
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product. 
Če vam je zdravnik povedal, da ne prenašate nekaterih sladkorjev, se pred jemanjem tega zdravila pogovorite z njim.
Patients with a history of suicide-related events or those exhibiting a significant degree of suicidal thoughts prior to commencement of treatment are known to be at greater risk of suicidal thoughts or suicidal behaviour, and should receive careful monitoring during treatment. 
Znano je, da pri bolnikih s samomorom povezanimi dogodki v anamnezi, ali bolnikih, ki kažejo znatno stopnjo samomorilne miselnosti pred uvedbo zdravljenja, obstaja večje tveganje za samomorilne misli ali poskusov samomora in jih je treba med zdravljenjem skrbno spremljati.
It weakly inhibits dopamine reuptake with no significant affinity for histaminergic, dopaminergic, cholinergic and adrenergic receptors. 
Šibko zavira prevzem dopamina brez pomembne afinitete za histaminergične, dopaminergične, holinergične in adrenergične receptorje.
Abrupt discontinuation should be avoided. 
Izogibati se moramo nenadni prekinitvi zdravljenja.
The safety and efficacy of duloxetine for the treatment of diabetic peripheral neuropathic pain has not been studied. 
Varnost in učinkovitost duloksetina za zdravljenje bolečine periferne diabetične nevropatije nista bili dokazani.
Stevens-Johnson Syndrome6 
StevensJohnsonov sindrom6
• night sweats, hives, cold sweats, sensitivity to sunlight, increased tendency to bruise 
• nočno potenje, koprivnica, hladen znoj, občutljivost na sončno svetlobo, povečano nagnjenje k modricam
These two studies included a 10 week placebo and active (fluoxetine) controlled acute phase followed by six months period of active controlled extension treatment. 
Ti dve študiji sta obsegali 10-tedensko akutno fazo s placebom in aktivno kontrolo (fluoksetinom), čemur je sledilo 6mesečno podaljšano obdobje z aktivno kontrolo.
If concomitant treatment with duloxetine and other serotonergic agents that may affect the serotonergic and/or dopaminergic neurotransmitter systems is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases. 
Če je sočasno zdravljenje z duloksetinom in drugimi serotonergičnimi zdravili, ki lahko vplivajo na serotonergične in/ali dopaminergične nevrotransmiterske sisteme klinično upravičeno, je priporočljivo bolnika skrbno nadzirati, še posebej med uvajanjem zdravljenja in pri zviševanju odmerkov.
Elimination The elimination half-life of duloxetine ranges from 8 to 17 hours (mean of 12 hours). 
Razpolovni čas izločanja duloksetina je od 8 do 17 ur (povprečno 12 ur).
For patients who experience a sustained increase in blood pressure while receiving duloxetine either dose reduction or gradual discontinuation should be considered (see section 4.8). 
Pri bolnikih, ki so doživeli vztrajno povišanje krvnega tlaka medtem, ko so prejemali duloksetin, je potrebno pretehtati znižanje odmerka ali postopno ukinitev (glejte poglavje 4 8).